Walleye Capital’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.34M Buy
20,800
+4,300
+26% +$303K 0.01% 1807
2025
Q4
$1.11M Buy
16,500
+16,400
+16,400% +$1.1M ﹤0.01% 2349
2025
Q3
$7.33K Sell
100
-1,100
-92% -$73.1K ﹤0.01% 4298
2025
Q2
$62.4K Sell
1,200
-2,200
-65% -$125K ﹤0.01% 3964
2025
Q1
$217K Buy
+3,400
New +$198K ﹤0.01% 3210
2024
Q4
Sell
-7,500
Closed -$429K 5122
2024
Q3
$429K Buy
7,500
+4,700
+168% +$269K ﹤0.01% 3439
2024
Q2
$147K Sell
2,800
-3,100
-53% -$136K ﹤0.01% 4508
2024
Q1
$240K Buy
5,900
+4,000
+211% +$150K ﹤0.01% 3849
2023
Q4
$70.2K Sell
1,900
-2,900
-60% -$109K ﹤0.01% 4196
2023
Q3
$183K Sell
4,800
-6,000
-56% -$246K ﹤0.01% 3609
2023
Q2
$390K Buy
+10,800
New +$368K ﹤0.01% 2619
2023
Q1
Sell
-33,200
Closed -$1.89M 4110
2022
Q4
$1.89M Buy
33,200
+28,100
+551% +$1.44M 0.03% 619
2022
Q3
$202K Buy
+5,100
New +$225K ﹤0.01% 2112
2019
Q4
Sell
-4,400
Closed -$68K 1981
2019
Q3
$68K Sell
4,400
-18,900
-81% -$311K ﹤0.01% 1522
2019
Q2
$400K Buy
+23,300
New +$376K 0.04% 599

Other funds holding HALO

Walleye Capital's HALO Position: Q1 2026 in Review

Walleye Capital increased its Halozyme (HALO) stake by 19% in Q1 2026, buying an estimated $613K and bringing the position to 53,364 shares worth $3.45M. The position accounts for 0.01% of the portfolio, ranked #1043.

Walleye Capital first reported a position in HALO in Q2 2019 and has held it in 14 quarters since. The position peaked at $9.81M in Q2 2024. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Walleye Capital held 53,364 shares of Halozyme worth $3.45M as of Q1 2026.
  • Walleye Capital bought 8,696 Halozyme shares in Q1 2026, an estimated $613K.
  • Halozyme made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1043 holding.
  • Walleye Capital first reported a position in Halozyme in Q2 2019 and has held it in 14 quarters since.
  • Walleye Capital's Halozyme position peaked at $9.81M in Q2 2024.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.